Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)2156-2157
Number of pages2
JournalJournal of Urology
Volume185
Issue number6
DOIs
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Urology

Cite this